Well what did they do with the money raised in 2011?
The Private Placement
As of August 2011, Therapy Cells, Inc. (f/k/a Diamond Information Institute, Inc.), a Wyoming corporation (the "Company"), intends to raise $5 Million through its private placement of preferred Series D stock being made in a transaction exempt from registration under the Securities Act of 1933, as amended (the "Act"), pursuant to Section 4(2) of the Act and Rule 506 of Regulation D promulgated under such section of the Act. The private offering commenced on or about August 2011 and is continuing. The Company's private placement seeks a maximum of $5,000,000 of total capital (including the overallotment provision) by offering up to 2,000,000 shares of preferred Series D stock at $2.50 per share. The placement is being made only to prospective investors who qualify as "accredited investors" as defined in Rule 501 of Regulation D of the Act. The capital raised in the private placement is expected to be utilized as follows: (1) $780,000 to operating expenses; (2) $450,000 to marketing; (3) $1,800,000 to pay for FDA approval, consultants, and related expenses; (4) $1,000,000 to research and development; (5) $970,000 held in a cash reserve. The Company plans to continue the private offering of the shares in the private placement until September 30, 2011, but, may extend the time of the offering in accordance with its terms.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
News 
Market Data 
Discover 
